Sep 23, 2024
Pharmascience Canada launches a new medication for its patient
Aug 31, 2020
Pharmascience Inc. reiterates its support to the Montreal Heart Institute's colchicine repurposing research studies in cardiovascular medicine and COVID-19
Mar 18, 2020
Pharmascience Inc. launches pms-FLUTICASONE PROPIONATE/SALMETEROL DPI for the maintenance treatment of asthma and COPD
Nov 16, 2019
Pharmascience Inc. contributes to the Montreal Heart Institute's COLchicine Cardiovascular Outcome Trial (COLCOT), a landmark study to benefit cardiovascular patients and the healthcare system
Oct 31, 2019
Pharmascience Inc. launches pms-FINGOLIMOD for the treatment of relapsing-remitting multiple sclerosis (MS) in adults
May 10, 2019
Pharmascience Inc. launches Royalmount Laboratories, a new analytical service division in Montreal
Apr 03, 2019
Pivot Pharma Signs Letter of Intent with Pharmascience Inc.
Mar 29, 2019
Pharmascience Inc. launches (Pr)pms-PROGESTERONE 200 mg capsule indicated as an adjunct to postmenopausal estrogen replacement therapy
Mar 09, 2019
Information Update - Multiple Losartan-containing drugs voluntarily recalled because of potential for nitrosamine impurity
Jul 04, 2018
Pharmascience Inc. launches (Pr)pms-TRANDOLAPRIL, first generic bioequivalent to (Pr)MAVIK® available on the market, for the treatment of mild to moderate essential hypertension
May 14, 2018
Pharmascience Inc. Launches (Pr)pms-NITROFURANTOIN, First Generic Bioequivalent to MacroBID® Available on the Market, for the Treatment of Urinary Tract Infections
Nov 16, 2017
RDD Pharma Raises $9.5M in Series B Funding to Fuel Global Development
Sep 20, 2017
Pendopharm, a division of Pharmascience Inc., Invests in Ontario based Edesa Biotech and Licenses Three Novel Anorectal Treatments for Canada